THE GENETIC PUZZLE: A CASE OF NOONAN SYNDROME WITH A NOVEL RAF1 MUTATION IN INDIA AND THE CHALLENGES OF DIAGNOSIS AND MANAGEMENT
Main Article Content
Keywords
Noonan Syndrome; dysmorphism, mutation; RAF1 gene; hypertrophic cardiomyopathy.
Abstract
We present a 17-month-old toddler with failure to thrive, developmental delay, characteristic facial dysmorphism, and a cardiac murmur suggestive of Noonan Syndrome. Echocardiography revealed hypertrophic cardiomyopathy, and molecular genetic testing confirmed the diagnosis, identifying a previously unreported RAF1 gene mutation (p.Thr260Lys) in India. The child was initiated on beta-blockers and received feeding advice, resulting in modest growth improvement over two months. Genetic testing further emphasized the importance of cascade screening. The child continues to receive multidisciplinary follow-up care under Paediatric OPD , Indira Gandhi Hospital, Dwarka. This case highlights the clinical significance of molecular testing in confirming Noonan Syndrome, particularly in cases with atypical or novel mutations. It also reflects the practical challenges faced by paediatricians in resource-limited healthcare settings, where barriers such as lack of awareness, financial constraints, and limited availability of genetic testing persist. Despite these limitations, genetic confirmation not only refines diagnosis and management but also provides valuable insight into at-risk individuals through family screening. Early recognition and comprehensive management can substantially improve outcomes and quality of life in affected children. Furthermore, the emotional, financial, and social stress experienced by caregivers of children with rare genetic disorders must be acknowledged, with the establishment of support systems to help families navigate these challenges.
References
2. Mendez HM, Opitz JM. Noonan syndrome: a review. Am J Med Genet. 1985;21:493– 506.
3. Gupta A, Gulati S, Kabra M. Genetic testing in children: challenges and opportunities in India. Indian Pediatr. 2018;55(7):593–599.
4. Ministry of Health and Family Welfare, Government of India. National Policy for Rare Diseases, 2021. Available from: https://main.mohfw.gov.in.
5. Maheshwari M, Belmont J, Fernbach S, et al. PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13. Hum Mutat. 2002;20:298– 304.
6. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29:465–468.
7. Tartaglia M, Kalidas K, Shaw A, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype–phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet. 2002;70:1555–1563.
8. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295–308.
9. Matozaki T, Murata Y, Saito Y, Okazawa H, Ohnishi H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 2009;100:1786–1793.
10. Patton MA. Noonan syndrome: a review. Growth Genet Horm. 1994;33:1–3.
11. Shaw AC, Kalidas K, Crosby AH, Jeffery S, Patton MA. The natural history of Noonan syndrome: a long-term follow-up study. Arch Dis Child. 2007;92:128–132.
12. Sanchez-Cascos A. The Noonan syndrome. Eur Heart J. 1983;4:223–229.
13. Aggarwal S, Phadke SR. Medical genetics and genomic medicine in India: current status and opportunities ahead. Mol Genet Genomic Med. 2015;3(3):160–171.
